Integra Lifesciences Q1 results beat estimates

Integra LifeSciences Holdings

05/05/2026 11:19

Overview

US medical technology firm's Q1 revenue rose 2.4%, beating analyst expectations

Adjusted EPS for Q1 beat consensus

Company reaffirmed 2026 revenue guidance and raised adjusted EPS outlook

Outlook

Integra Lifesciences expects Q2 revenue between $410 mln and $425 mln

Company sees Q2 adjusted EPS in a range of $0.44 to $0.52

Integra Lifesciences raises 2026 adj EPS guidance to $2.40-$2.50, reaffirms revenue outlook

Result Drivers

TISSUE RECONSTRUCTION GROWTH - Strong growth in Integra Skin, DuraSorb, and the relaunch of PriMatrix drove mid-single digit growth in wound reconstruction; private label sales also rose, per company

SUPPLY RELIABILITY - Improved supply reliability supported strong growth in Integra Skin and return to market with PriMatrix and Durepair, according to CEO Stuart Essig

SEGMENT PERFORMANCE MIX - Organic growth in Neuro was offset by declines in Instruments and ENT, with instrument sales affected by order timing, per company

Company press release: ID:nGNX9NlFFj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$391.9 mln
$381.87 mln (8 Analysts)
Q1 Adjusted EPS
Beat
$0.54
$0.40 (8 Analysts)
Q1 EPS
-$0.06
Q1 Adjusted Net Income
$41.6 mln
Q1 Adjusted EBITDA
$76.2 mln
Q1 Adjusted Gross Margin
64.1%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Integra Lifesciences Holdings Corp is $13.00, about 22.1% above its May 4 closing price of $10.65

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 5 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)